A phase 3 study to evaluate the safety and efficacy of TAK-390MR [dexlansoprazole] (60 Mg QD and 90 Mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis.

Trial Profile

A phase 3 study to evaluate the safety and efficacy of TAK-390MR [dexlansoprazole] (60 Mg QD and 90 Mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Registrational; Therapeutic Use
  • Sponsors TAP Pharmaceutical Products
  • Most Recent Events

    • 01 Nov 2009 Primary endpoint 'Disease recurrence rate' has been met.
    • 01 Nov 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
    • 01 Sep 2009 Actual patient number (451) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top